Margaux Geier

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Nathalie Baize, I. Monnet, Laurent Greillier et al. · The Lancet Oncology · 2020 · 153 citations

Medicine, Oncology, Pharmacology +13

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

Karim Amrane, Margaux Geier, R. Corre et al. · Cancer Medicine · 2020 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).

H. Léna, Isabelle Monnet, Olivier Bylicki et al. · Journal of Clinical Oncology · 2022 · 35 citations

Medicine, Oncology, Pharmacology +14

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study

D. Arpin, Marie-Christine Charpentier, I. Monnet et al. · Therapeutic Advances in Medical Oncology · 2020 · 26 citations · Full text

Medicine, Oncology, Pathology +17

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

Olivier Bylicki, Pascale Tomasini, Radj Gervais et al. · European Journal of Cancer · 2023 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17